The Platform
2011 
- Presented safety data from the Phase 1 trial of GRNOPC1 at the Pre-Conference Symposia of the joint 2011 American Congress of Rehabilitation Medicine and American Society of Neuro-Rehabilitation Annual Meeting showing that the lowest intended dose of GRNOPC1 administered to four patients with complete thoracic spinal cord injuries was well tolerated with no serious adverse events.
2010
- First human cellular assay product derived from hESCs for use in drug discovery and toxicity screening launched by GE Healthcare
- First patient received GRNOPC1 in Phase 1 clinical trial for spinal cord injury
- Collaboration established with University Campus Suffolk to develop hESC-derived chondrocytes for the treatment of cartilage damage and joint disease
- New synthetic matrix product for growing hESCs launched by Corning
2009
- Publication in Regenerative Medicine demonstrating that dendritic cells derived from hESCs exhibit normal function
Read Publication - FDA grants clearance to begin world's first clinical trial of hESC-based therapy, GRNOPC1 in patients with spinal cord injury
2007
- Publication in Stem Cells showing islet like clusters derived from hESCs secrete insulin in response to elevated glucose levels
Read Publication - Publication in Stem Cells and Development demonstrating GRNOPC1 produces multiple nerve growth factors (proteins that stimulate the survival and regeneration of neurons)Read Publication
2006
- Collaboration established with University of Edinburgh to conduct preclinical safety and efficacy studies with hESC-derived cells, including hepatocytes for the treatment of liver failure and osteoblasts and chondrocytes for the treatment of musculoskeletal disorders, bone fractures and osteoporosis
- New protocols for differentiation of islet cells from hESCs presented at the Stem Cells & Regenerative Medicine Meeting
2005
- Publication in American Journal of Pathology showing that cardiomyocytes differentiated from hESCs engraft when transplanted into the rat heartRead Publication
- Publication in Journal of Neuroscience showing that oligodendrocyte progenitors differentiated from hESCs produce functional improvements in rats with spinal cord injuriesRead Publication
- Publication in Journal of Experimental Medicine demonstrating that hematopoietic stem cells derived from hESCs can engraft and establish hematopoiesis in animalsRead Publication
- Publication in the journal Stem Cells demonstrating that hESCs can be grown with defined growth factors, enabling scaled production of therapeutic cellsRead Publication
2004
- Publication in Stem Cells demonstrating that hESCs have unique immune-privileged propertiesRead Publication
2003
- First presentation demonstrating that the transplant of oligodendrocyte progenitor cells derived from hESCs can result in functional improvement in animals with spinal cord injuries at Society for Neurosciences Annual Meeting
- Publication in Cloning & Stem Cells showing derivation of osteoblasts from hESCsRead Publication
- Publication in Blood showing derivation of hematopoietic cells from hESCsRead Publication
2002
- Publication in Circulation Research showing the differentiation of cardiomyocytes from hESCsRead Publication
2001
- Publication in Experimental Neurology showing the derivation of neurons and neural precursors from hESCsRead Publication
- Publication in Nature Biotechnology demonstrating the culture of hESCs in the absence of direct feeder cell support to facilitate scalable manufacturing of hESC-derived therapiesRead Publication
1998
- Publication in PNAS reporting first derivation of hESCs from germ cells at Johns Hopkins University (worked funded by Geron)Read Publication
- Publication in Science reporting first derivation of hESCs at the University of Wisconsin (work funded by Geron)Read Publication
